Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18–49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study

Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18–49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study

<b>Background</b>: Protein-based pneumococcal vaccines (PBPVs) may offer expanded protection against <i>Streptococcus pneumoniae</i> and tackle the antimicrobial resistance crisis in pneumococcal infections. This study examined the safety and immunogenicity in healthy adults...

Full description

Bibliographic Details
Main Authors: Yanxia Wang, Gang Shi, Xue Wang, Zhiqiang Xie, Jinbo Gou, Lili Huang, Haitao Huang, Wangyang You, Ruijie Wang, Yongli Yang, Feiyu Wang, Tao Zhu, Dongyang Zhao
Format: Article
Language:English
Published: MDPI AG 2024-07-01
Series:Vaccines
Subjects:
protein-based pneumococcal vaccine
pneumococcal surface protein A
pneumolysin protein
immunogenicity
Online Access:https://www.mdpi.com/2076-393X/12/8/827

Internet

https://www.mdpi.com/2076-393X/12/8/827

Similar Items